GlassScriptPhysician profile
Gilberto Heredia
NPI 1649299942
$2,969.04
in general payments reported to CMS, 2019-2025
21 companies · $577 in 2025
The $577 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $120 · 2022: $339 · 2023: $1,210 · 2024: $723 · 2025: $577.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,510.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,509.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $483.55 | 2023-2025 | Evenity, Repatha, Prolia |
| Astrazeneca Pharmaceuticals LP | $449.32 | 2022-2025 | Breztri, Fasenra |
| Novo Nordisk INC | $325.26 | 2022-2025 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $287.32 | 2022-2025 | Jardiance, Stiolto Respimat, Spiriva Respimat |
| Lilly USA, LLC | $200.19 | 2022-2025 | Zepbound, Mounjaro, Emgality |
| Phathom Pharmaceuticals, INC. | $197.74 | 2024 | Voquezna |
| Novartis Pharmaceuticals Corporation | $178.09 | 2022-2023 | |
| Abbott Laboratories | $147.19 | 2023 | Freestyle Libre 2 |
| Abbvie INC. | $123.58 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $123.44 | 2023 | Rexulti |
| Idorsia Pharmaceuticals US INC | $121.36 | 2022 | |
| Dexcom, INC. | $106.07 | 2023 | Dexcom G7 Gss (161) |
| Indivior INC. | $52.12 | 2019 | |
| Astellas Pharma US INC | $45.99 | 2025 | Veozah |
| Allergan, INC. | $26.73 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $26.61 | 2019 | |
| Exact Sciences Corporation | $17.11 | 2025 | The Cologuard Plus Collection Kit |
| Janssen Pharmaceuticals, INC | $15.71 | 2023 | Xarelto |
| Glaxosmithkline, LLC. | $15.07 | 2025 | Arexvy, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.39 | 2019 | |
| Pfizer INC. | $12.20 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gilberto Heredia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.